CORV - Correvio Pharma Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.4300
-0.0700 (-2.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.5000
Open2.4900
Bid0.0000 x 1400
Ask0.0000 x 1400
Day's Range2.3100 - 2.5000
52 Week Range1.4300 - 4.4900
Volume92,322
Avg. Volume143,714
Market Cap122.333M
Beta (3Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-0.8790
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.84
Trade prices are not sourced from all markets
  • CNW Group

    Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    VANCOUVER , Sept. 12, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S. Food and Drug Administration (FDA) has accepted for review United Therapeutics Corporation's (UTHR) New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH).  The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020 .  Trevyent is a drug-device combination product that combines two-day, single use, disposable PatchPump® technology with treprostinil, for the subcutaneous treatment of PAH. Correvio holds commercial rights to Trevyent for the international markets of Europe and the Middle East and expects to file regulatory submissions for Trevyent in Europe in mid-2020.

  • CNW Group

    Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  • PR Newswire

    Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

    VANCOUVER, Sept. 3, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of results from the SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV), the Company's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), at the European Society of Cardiology (ESC) 2019 Congress taking place August 31 – September 4, 2019, in Paris, France. SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010.  In this prospective and retrospective, international, multicenter, observational registry, 1,778 unique patients with 2,009 treatment episodes were enrolled to describe patients receiving Brinavess and to characterize normal conditions of use and dosing, and quantify possible medically significant risks associated with the use of Brinavess in real-world clinical practice.  The data for SPECTRUM was provided by 53 participating hospitals in the EU and demonstrated that treatment with Brinavess successfully converted 70.2% (95% confidence interval [CI] 68.1 – 72.2) of all treated episodes.  Treatment with Brinavess also showed a median time to conversion of 12 minutes from start of first infusion among patients who converted.

  • PR Newswire

    Correvio Reports Second Quarter 2019 Financial Results

    FDA Accepts New Drug Application for Brinavess TM ; PDUFA Date Set for December 24, 2019 Recently Strengthened Balance Sheet Extends Cash Runway Into Mid-2020 Management to Host Conference Call and Webcast ...

  • PR Newswire

    Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress

    NASDAQ: CORV   TSX: CORV VANCOUVER , Aug. 12, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced ...

  • CNW Group

    Correvio to Report Second Quarter 2019 Financial Results

    Correvio to Report Second Quarter 2019 Financial Results

  • PR Newswire

    Correvio Closes Public Offering of 9,200,000 Common Shares

    VANCOUVER, Aug. 7, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the closing of its previously announced underwritten public offering (the "Offering") of 9,200,000 common shares, which includes the exercise of the underwriter's over-allotment option in full, from treasury at a price to the public of US$1.50 per common share, for aggregate gross proceeds to the Company of US$13,800,000, before deducting the underwriting commission and estimated Offering expenses payable by the Company.

  • PR Newswire

    Correvio Announces Pricing Of Public Offering Of Common Shares

    VANCOUVER, Aug. 2, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced the size and pricing of its previously announced underwritten public offering (the "Offering") of 8,000,000 common shares from treasury at a price to the public of US$1.50 per common share, for aggregate gross proceeds to the Company of US$12,000,000, before deducting the underwriting commission and estimated Offering expenses payable by the Company. In addition, Correvio has also granted the underwriter of the Offering a 30-day option to purchase up to an additional 1,200,000 common shares on the same terms and conditions.

  • CNW Group

    Correvio Announces Overnight Marketed Offering of Common Shares

    VANCOUVER , Aug. 1, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has undertaken an overnight marketed underwritten public offering (the "Offering") of its common shares. In addition, Correvio expects to grant the underwriters of the Offering a 30-day option to purchase up to an additional 15% percent of the number of common shares sold in the Offering on the same terms and conditions.

  • PR Newswire

    U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)

    VANCOUVER, July 25, 2019 /PRNewswire/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adult patients.  The FDA assigned a target action date of December 24, 2019 under the Prescription Drug User-Fee Act (PDUFA).  In its acceptance letter, the FDA stated that it is currently planning to hold an advisory committee meeting to discuss this application.

  • Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Correvio Pharma Corp. (CORV)

    Is Correvio Pharma Corp. (NASDAQ:CORV) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]

  • CNW Group

    Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation

    VANCOUVER , June 24, 2019 /CNW/ - Correvio Pharma Corp. (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Brinavess™ (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF). "The resubmission of the Brinavess NDA is a major milestone for Correvio and is the culmination of substantial effort by our employees and the investigators who have dedicated themselves toward investigating this potential new treatment option for adult patients with recent onset AF," said Mark H.N. Corrigan , MD, CEO of Correvio.

  • CNW Group

    Correvio Announces Voting Results

    Correvio Announces Voting Results

  • Associated Press

    Correvio: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 23 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...